Trial · NCT02036970
Participant flow220
How many started, completed or left each group, period by period.
1 to 20 of 220
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part 1: Day 1 Through Week 16 | STARTED | Part 1: Dose-Ranging Bardoxolone Methyl 2.5 mg/Part 2: Open-Label | 6 | |
| Part 1: Day 1 Through Week 16 | STARTED | Part 1: Dose-Ranging Bardoxolone Methyl 5 mg/Part 2: Open-Label | 12 | |
| Part 1: Day 1 Through Week 16 | STARTED | Part 1: Dose-Ranging Bardoxolone Methyl 10 mg/Part 2: Open-Label | 11 | |
| Part 1: Day 1 Through Week 16 | STARTED | Part 1: Dose-Ranging Bardoxolone Methyl 20 mg/Part 2: Open-Label | 12 | |
| Part 1: Day 1 Through Week 16 | STARTED | Part 1: Dose-Ranging Placebo 2.5 mg/Part 2: Bardoxolone Methyl 2.5 mg | 2 | |
| Part 1: Day 1 Through Week 16 | STARTED | Part 1: Dose-Ranging Placebo 5 mg/Part 2: Bardoxolone Methyl 5 mg | 4 | |
| Part 1: Day 1 Through Week 16 | STARTED | Part 1: Dose-Ranging Placebo 10 mg/Part 2: Bardoxolone Methyl 10 mg | 3 | |
| Part 1: Day 1 Through Week 16 | STARTED | Part 1: Dose-Ranging Placebo 20 mg/Part 2: Bardoxolone Methyl 20 mg | 4 | |
| Part 1: Day 1 Through Week 16 | STARTED | Part 1: Dose Titration: Bardoxolone Methyl 10 mg/Part 2: Bardoxolone Methyl 10 mg | 74 | |
| Part 1: Day 1 Through Week 16 | STARTED | Part 1: Dose Titration: Placebo 10 mg/Part 2: Bardoxolone Methyl 10 mg | 38 | |
| Part 1: Day 1 Through Week 16 | Cohort 1: PAH (BL 6MWD <= 450 Meters) | Part 1: Dose-Ranging Bardoxolone Methyl 2.5 mg/Part 2: Open-Label | 6 | |
| Part 1: Day 1 Through Week 16 | Cohort 1: PAH (BL 6MWD <= 450 Meters) | Part 1: Dose-Ranging Bardoxolone Methyl 5 mg/Part 2: Open-Label | 6 | |
| Part 1: Day 1 Through Week 16 | Cohort 1: PAH (BL 6MWD <= 450 Meters) | Part 1: Dose-Ranging Bardoxolone Methyl 10 mg/Part 2: Open-Label | 11 | |
| Part 1: Day 1 Through Week 16 | Cohort 1: PAH (BL 6MWD <= 450 Meters) | Part 1: Dose-Ranging Bardoxolone Methyl 20 mg/Part 2: Open-Label | 6 | |
| Part 1: Day 1 Through Week 16 | Cohort 1: PAH (BL 6MWD <= 450 Meters) | Part 1: Dose-Ranging Placebo 2.5 mg/Part 2: Bardoxolone Methyl 2.5 mg | 2 | |
| Part 1: Day 1 Through Week 16 | Cohort 1: PAH (BL 6MWD <= 450 Meters) | Part 1: Dose-Ranging Placebo 5 mg/Part 2: Bardoxolone Methyl 5 mg | 2 | |
| Part 1: Day 1 Through Week 16 | Cohort 1: PAH (BL 6MWD <= 450 Meters) | Part 1: Dose-Ranging Placebo 10 mg/Part 2: Bardoxolone Methyl 10 mg | 3 | |
| Part 1: Day 1 Through Week 16 | Cohort 1: PAH (BL 6MWD <= 450 Meters) | Part 1: Dose-Ranging Placebo 20 mg/Part 2: Bardoxolone Methyl 20 mg | 2 | |
| Part 1: Day 1 Through Week 16 | Cohort 1: PAH (BL 6MWD <= 450 Meters) | Part 1: Dose Titration: Bardoxolone Methyl 10 mg/Part 2: Bardoxolone Methyl 10 mg | 0 | |
| Part 1: Day 1 Through Week 16 | Cohort 1: PAH (BL 6MWD <= 450 Meters) | Part 1: Dose Titration: Placebo 10 mg/Part 2: Bardoxolone Methyl 10 mg | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02036970/flow